<DOC>
	<DOCNO>NCT02342769</DOCNO>
	<brief_summary>TRIUMPH prospective , non-interventional observational study use fixdose combination TRIUMEQ ( Dolutegravir/Abacavir/Lamivudine ) respective monitoring measure practice HIV care Germany . The primary study objective descriptive report incidence therapeutic monitoring measure HIV-infected patient TRIUMEQ therapy everyday routine practice Germany . The study design enroll approximately 400 patient . There protocol-mandated visit procedure associate study . Each patient expect participate maximum 3 year premature discontinuation ( i.e. , discontinuation TRIUMEQ , due death , withdrawal consent , lose follow-up . TRIUMEQ register trademark ViiV Healthcare group company .</brief_summary>
	<brief_title>Prospective Non-Interventional Observational Study Use TRIUMEQ Corresponding Monitoring Measures Clinical Practice Germany</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Documented HIV infection Age â‰¥ 18 year HLAB*5701negative Decision first initiation TRIUMEQ therapy make attend physician independent inclusion observational study Prior dolutegravir therapy ( cf . also Capping ABC section 3.3 Recruitment ) Participation clinical trial study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>